Tyra Bioscience (TYRA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on the stock and has a $30.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mitchell Kapoor has given his Buy rating due to a combination of factors, primarily focusing on the promising development of TYRA-300 for treating low-grade, intermediate risk non-muscle invasive bladder cancer (IR NMIBC). The initiation of the Phase 2 trial, which will evaluate the efficacy and safety of TYRA-300, marks a significant step forward, with initial data expected in the first half of 2026. This trial aims to demonstrate a complete response rate that is competitive with current treatments, offering a potentially more convenient oral administration compared to traditional procedures like TURBT.
Moreover, TYRA-300’s potential success could provide a unique advantage in the NMIBC treatment landscape, especially given its oral route of administration, which may be preferred by patients for its convenience and reduced need for hospital visits. Additionally, the economic incentives for urologists to prescribe TYRA-300 through the UroGPO channel could further enhance its market adoption. These factors collectively support Kapoor’s positive outlook and Buy rating for Tyra Bioscience’s stock.
In another report released yesterday, Oppenheimer also reiterated a Buy rating on the stock with a $30.00 price target.